| Generic Name | Brand Name |
|---|---|
| interferon alfa-2a | Roferon A |
| interferon alfa-2b | Intron A |
Interferon is usually given as a shot under the skin.
Interferon is a man-made copy of a protein that is produced by the body in response to infection. It helps the immune system fight disease and may slow or stop the growth of cancer cells. It can make cancer cells too weak to protect themselves from the immune system.
Interferon may be used to treat some leukemias and other diseases, such as melanoma that has spread to the lymph nodes and chronic hepatitis C.
Research shows that interferon is better than busulfan or hydroxyurea in treating CML. But interferon also causes more side effects.1
The use of interferon may increase the survival rate of some people with melanoma.2
Side effects of treatment with interferon are common and may include:
Rare side effects include:
See Drug Reference for a full list of side effects. (Drug Reference is not available in all systems.)
Interferon should be used only under the supervision of a medical oncologist or hematologist. When interferon is used for chronic viral hepatitis, a hepatologist or gastroenterologist is most likely to supervise treatment.
Interferon may be combined with cytarabine or imatinib to treat CML. It can also be used with other drugs to treat melanoma or kidney cancer.
Clinical trials are studying the use of interferon for melanoma that has spread or come back.
Interferon can cause birth defects. Taking this medicine is not recommended if you wish to become pregnant or to father a child while you are taking it. But for young women with chronic myelogenous leukemia (CML) who are pregnant, there may be less risk in taking this medicine compared to other medicines, such as tyrosine kinase inhibitors (TKIs).
Do not use alcohol or illegal drugs while you are being treated with interferon.
Complete the new medication information form (PDF)(What is a PDF document?) to help you understand this medication.
Citations
- Reichard KK, et al. (2009). Chronic myeloid leukemia. In JP Greer et al., eds., Wintrobe's Clinical Hematology, 12th ed., vol. 2, pp. 2006–2030. Philadelphia: Lippincott Williams and Wilkins.
- Kirkwood JM, et al. (2004). A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clinical Cancer Research, 10(5): 1670–1677.
Last Revised: December 17, 2010
Author: Healthwise Staff
Medical Review: Kathleen Romito, MD - Family Medicine & Brian Leber, MDCM, FRCPC - Hematology
This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.
To learn more visit Healthwise.org
© 1995-2012 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.
RT @sanfordtimg: #sanfordresearch's Dr. Amy Elliott is filling @keloland in on the CRCAIH Annual Summit http://t.co/brWO1zbKUd